Abstract | PURPOSE: EXPERIMENTAL DESIGN: Since July 2007, five patients with progressive metastatic ASPS have been treated with continuous SM 37.5 mg/d on a named basis. Four patients are evaluable for response. In four cases, cryopreserved material was available. Upstream and downstream targets of receptor tyrosine kinase (RTK) pathways, as well as mechanisms of activation, were investigated by biochemical profiles, including human phospho-receptor RTK antibody arrays and immunoprecipitation/Western blotting, molecular analyses, immunohistochemistry, and fluorescence in situ hybridization analyses. RESULTS: CONCLUSION: SM may have antitumor activity in ASPS, possibly through a mechanism involving PDGFR and RET. The role of MET, epidermal growth factor receptor, and mTOR, as well as PDGFR inhibition, needs to be further explored.
|
Authors | Silvia Stacchiotti, Elena Tamborini, Andrea Marrari, Silvia Brich, Sara Arisi Rota, Marta Orsenigo, Flavio Crippa, Carlo Morosi, Alessandro Gronchi, Marco A Pierotti, Paolo G Casali, Silvana Pilotti |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 3
Pg. 1096-104
(Feb 01 2009)
ISSN: 1078-0432 [Print] United States |
PMID | 19188185
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indoles
- Protein Kinase Inhibitors
- Pyrroles
- Protein Kinases
- MTOR protein, human
- ErbB Receptors
- Receptor Protein-Tyrosine Kinases
- Receptors, Platelet-Derived Growth Factor
- Receptors, Vascular Endothelial Growth Factor
- Proto-Oncogene Proteins c-akt
- TOR Serine-Threonine Kinases
- Sunitinib
|
Topics |
- Adult
- Drug Evaluation
- ErbB Receptors
(metabolism)
- Female
- Humans
- Indoles
(therapeutic use)
- Male
- Middle Aged
- Phosphorylation
- Protein Kinase Inhibitors
(therapeutic use)
- Protein Kinases
(metabolism)
- Proto-Oncogene Proteins c-akt
(metabolism)
- Pyrroles
(therapeutic use)
- Receptor Protein-Tyrosine Kinases
(metabolism)
- Receptors, Platelet-Derived Growth Factor
(metabolism)
- Receptors, Vascular Endothelial Growth Factor
(metabolism)
- Sarcoma, Alveolar Soft Part
(drug therapy, metabolism)
- Signal Transduction
(drug effects)
- Sunitinib
- TOR Serine-Threonine Kinases
|